AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.

Pharmalittle: We're reading about another AstraZeneca trial failure, a Novo name change, and more

Novo Nordisk will shorten its name for day-to-day use to just Novo in a bid to become more recognizable in its obesity market war with Lilly.

AstraZeneca’s next-gen SERD disappoints in untreated advanced breast cancer

AstraZeneca said Friday that its recently approved breast cancer drug Etcamah failed a late-stage trial designed to support a label expansion into an earlier setting. Just last week, the FDA cleared the ...